Kaplan Fox Alerts Investors of Iovance Biotherapeutics, Inc. (IOVA) to the Lead Plaintiff Deadline on July 14, 2025
NEW YORK, NY - May 24, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ('Iovance' or the 'Company') (NASDAQ: IOVA) on behalf of investors that purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025 (the 'Class Period').
CLICK HERE TO JOIN THE CASE
If you are an investor in Iovance and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than July 14, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
On May 8, 2025, after the markets closed, Iovance announced its first quarter 2025 financial results. The Company revealed that total product revenue for the quarter was $49.3 million, a decline from the prior quarter's reported revenue of $73.7 million. The Company also disclosed that full fiscal year 2025 revenue guidance was being revised to $250 million to $300 million from previous guidance of $450 million to $475 million. Iovance stated that it was 'revising full-year 2025 revenue guidance to reflect recent launch dynamics' of the Company's T cell immunotherapy, Amtagvi (lifileucel). Amtagvi was approved by the U.S. Food and Drug Administration in February 2024 and was commercially launched in the first half of 2024.
Following this news, the price of Iovance stock fell $1.42 per share, nearly 45%, to close at $1.75 per share on May 9, 2025.
The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that Defendants, (i) new Authorized Treatment Centers were experiencing longer timelines to begin treating patients with Amtagvi; (ii) the Company's sales team and new ATCs were ineffective in patient identification and patient selection for Amtagvi, leading to higher patient drop-offs; and (iii) the foregoing dynamics led to higher costs and lower revenue because ATCs could not keep pace with manufactured product.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this Notice, your rights, or your interests, please contact:
CONTACT:
Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(212) 329-8571
[email protected]
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
[email protected]
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
https://www.kaplanfox.com/case/iovance-biotherapeutics-inc/
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Dollar General Stock Just Popped, but Is the Worst Really Behind It?
Dollar General is starting to benefit from more affluent customers trading down on their shopping choices. However, its core customer base remains under pressure. The stock, meanwhile, is no longer in the bargain bin after a strong rally. 10 stocks we like better than Dollar General › Dollar General (NYSE: DG) has struggled in recent years, as inflationary pressures hurt its lower-income consumer base. However, the stock staged a strong rally following its fiscal first-quarter earnings report. As of this writing, it is up 50% in 2025. Let's take a closer look at its most recent earnings report and commentary to see whether this rally is sustainable or if the worst is not really behind it just yet. On the surface, tariffs would seem to be a big negative for a company like Dollar General. After all, the retailer's core customer base was already feeling pressure from higher prices due to inflation, and it looked like it was losing share to big-box price leader Walmart (NYSE: WMT). However, the company has begun to see more higher-income consumers frequent its stores in search of value. The retailer said it plans to minimize the impact of tariffs on its gross margins as much as possible without raising prices, although it could increase prices as a last resort. It plans to do this by working with vendors to cut costs, moving some manufacturing to other countries, and tweaking its product lineup by making changes or swapping out certain items. It noted that a mid- to high-single-digit percentage of its overall purchases are directly imported from China, but about double that percentage comes indirectly from the country. The inroads with higher-income consumers contributed to a 2.4% increase in same-store sales in the quarter. While traffic fell by 0.3%, its average checkout ticket rose by 2.7%. Growth came from gains in the food, seasonal, and home & apparel categories. Same-store sales is a very important metric for Dollar General, as it has said in the past that it needs to grow its comparable-store sales by around 3% for it to leverage its expenses and grow its earnings. However, the composition matters, and growth from high-margin areas, such as seasonal items, helped power its earnings higher. This appears to be largely a reflection of higher-income consumers shopping at its locations, as well as its efforts to improve the customer experience and offer better merchandising in categories such as seasonal decor and home items. The company also said that its newer pOpshelf store concept -- which is meant to provide a fun and affordable shopping experience with a focus on home goods, seasonal decor, and party supplies -- performed well, exceeding expectations. Overall, Dollar General's revenue rose 5% year over year to $10.4 billion, while its earnings per share (EPS) jumped 8% to $1.78. That was well ahead of the analyst consensus of $10.3 billion in revenue and adjusted EPS of $1.48. Gross margin increased 78 basis points to 31%, helped by lower shrink and higher inventory markups. Shrink is the amount of merchandise that gets lost, damaged, spoiled, stolen, or just generally can't be sold, and the company has been working hard to improve this metric. Looking ahead, Dollar General raised its full-year guidance. It now expects revenue to grow between 3.7% and 4.7%, with same-store sales increasing between 1.5% and 2.5%. That's up from a prior outlook of revenue growth of 3.4% to 4.4% on comparable-store growth of 1.2% to 2.2%. Meanwhile, it raised the low end of its full-year EPS guidance to a range of $5.20 to $5.80, up from a previous forecast of between $5.10 and $5.80. It said that the guidance assumes that current tariff rates remain in place. Metric Prior Guidance Current Guidance Revenue growth 3.4% to 4.4% 3.7% and 4.7% Same-store sales growth 1.2% to 2.2% 1.5% and 2.5% Earnings per share $5.10 to $5.80 $5.20 to $5.80 Source: Dollar General. The company is also looking to add 575 new store openings in the U.S. this year and up to 15 in Mexico. Dollar General appears to be benefiting from the trade-down effect this year. This is something Walmart has been experiencing for a while, but something dollar stores like Dollar General had previously been missing out on. It was only last year that these companies were talking about how the current environment was one of the most difficult periods in their histories. And for dollar stores' core customer bases, things may actually be worse now with tariffs than they were last year. As such, whether Dollar General can continue to turn the corner likely depends largely on whether it can keep the higher-income customers that have begun to visit its stores and continue to attract new ones. Right now, the company is seeing these new customers visit more often and spend more money per visit. Its remodeling efforts, along with initiatives like its mobile app and own same-day delivery service and partnership with DoorDash, are also likely helping attract more affluent consumers. From a valuation perspective, the retailer now trades at a forward price-to-earnings (P/E) ratio of 20 based on analyst estimates for fiscal year 2025 (ending January 2026). That valuation shows the stock is no longer in the bargain bin. While Dollar General has made a lot of progress -- with its core consumer still very stressed -- I don't want to chase this rally at its current valuation. Before you buy stock in Dollar General, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Dollar General wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends DoorDash and Walmart. The Motley Fool has a disclosure policy. Dollar General Stock Just Popped, but Is the Worst Really Behind It? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
15 minutes ago
- Yahoo
Homes in Franklin County sold for higher prices recently: See how much here
Newly released data from for March shows that potential buyers and sellers in Franklin County saw higher home sale prices than the previous month's median of $259,000. The median home sold for $265,000, an analysis of data from shows. That means March, the most recent month for which figures are available, was up 2.3% from February. Compared to March 2024, the median home sales price was up 4.4% compared to $253,750. sources sales data from real estate deeds, resulting in a few months' delay in the data. The statistics don't include homes currently listed for sale and aren't directly comparable to listings data. Information on your local housing market, along with other useful community data, is available at Here is a breakdown on median sale prices: Looking only at single-family homes, the $263,000 median selling price in Franklin County was down 3.7% in March from $273,000 the month prior. Since March 2024, the sales price of single-family homes was up 2% from a median of $257, single family homes sold for $1 million or more during the month, compared to zero recorded transactions of at least $1 million in March 2024. Condominiums and townhomes increased by 26.8% in sales price during March to a median of $265,000 from $209,000 in February. Compared to March 2024, the sales price of condominiums and townhomes was up 28.5% from $206,300. No condominiums or townhomes sold for $1 million or more during March. In March, the number of recorded sales in Franklin County rose by 25.8% since March 2024 — from 128 to 161. All residential home sales totaled $61 million. Across Pennsylvania, homes sold at a median of $265,000 during March, up 1.9% from $259,998 in February. There were 9,945 recorded sales across the state during March, down 3.3% from 10,287 recorded sales in March 2024. Here's a breakdown for the full state: The total value of recorded residential home sales in Pennsylvania increased by 18.7% from $2.7 billion in February to $3.2 billion this March. Out of all residential home sales in Pennsylvania, 2.33% of homes sold for at least $1 million in March, up from 2.29% in March 2024. Sales prices of single-family homes across Pennsylvania increased by 1.9% from a median of $260,000 in February to $265,000 in March. Since March 2024, the sales price of single-family homes across the state was up 6% from $250,000. Across the state, the sales price of condominiums and townhomes rose 2% from a median of $255,916 in February to $261,000 during March. The median sales price of condominiums and townhomes is up 6.1% from the median of $245,892 in March 2024. The median home sales price used in this report represents the midway point of all the houses or units listed over the given period of time. The median offers a more accurate view of what's happening in a market than the average sales price, which would mean taking the sum of all sales prices then dividing by the number of homes sold. The average can be skewed by one particularly low or high sale. The USA TODAY Network is publishing localized versions of this story on its news sites across the country, generated with data from Please leave any feedback or corrections for this story here. This story was written by Ozge Terzioglu. Our News Automation and AI team would like to hear from you. Take this survey and share your thoughts with us. This article originally appeared on Waynesboro Record Herald: Homes in Franklin County sold for higher prices recently: See how much here
Yahoo
15 minutes ago
- Yahoo
Homes in Washington County sold for higher prices recently: See how much here
Newly released data from for March shows that potential buyers and sellers in Washington County saw higher home sale prices than the previous month's median of $299,500. The median home sold for $324,900, an analysis of data from shows. That means March, the most recent month for which figures are available, was up 8.5% from February. Compared to March 2024, the median home sales price was up 8.5% compared to $299,500. sources sales data from real estate deeds, resulting in a few months' delay in the data. The statistics don't include homes currently listed for sale and aren't directly comparable to listings data. Information on your local housing market, along with other useful community data, is available at Here is a breakdown on median sale prices: Looking only at single-family homes, the $342,500 median selling price in Washington County was up 12.3% in March from $305,000 the month prior. Since March 2024, the sales price of single-family homes was up 2.2% from a median of $335, single-family homes sold for $1 million or more during the month. Condominiums and townhomes decreased by 10.2% in sales price during March to a median of $247,000 from $274,999 in February. Compared to March 2024, the sales price of condominiums and townhomes was down 2.8% from $254,000. No condominiums or townhomes sold for $1 million or more during March. In March, the number of recorded sales in Washington County rose by 26.1% since March 2024 — from 142 to 179. All residential home sales totaled $59.9 million. Across Maryland, homes sold at a median of $398,894 during March, up 2.4% from $389,423 in February. There were 6,417 recorded sales across the state during March, down 1.8% from 6,534 recorded sales in March 2024. Here's a breakdown for the full state: The total value of recorded residential home sales in Maryland increased by 22.8% from $2.9 billion in February to $3.6 billion this March. Out of all residential home sales in Maryland, 7.14% of homes sold for at least $1 million in March, down from 7.73% in March 2024. Sales prices of single-family homes across Maryland increased by 4.5% from a median of $440,000 in February to $460,000 in March. Since March 2024, the sales price of single-family homes across the state was slightly up from $457,600. Across the state, the sales price of condominiums and townhomes is at a median of $325,000, the same as February. The median sales price of condominiums and townhomes is down 1.6% from the median of $330,333 in March 2024. The median home sales price used in this report represents the midway point of all the houses or units listed over the given period of time. The median offers a more accurate view of what's happening in a market than the average sales price, which would mean taking the sum of all sales prices then dividing by the number of homes sold. The average can be skewed by one particularly low or high sale. The USA TODAY Network is publishing localized versions of this story on its news sites across the country, generated with data from Please leave any feedback or corrections for this story here. This story was written by Ozge Terzioglu. Our News Automation and AI team would like to hear from you. Take this survey and share your thoughts with us. This article originally appeared on The Herald-Mail: Homes in Washington County sold for higher prices recently: See how much here
